Dr. Alex Carlisle holds a Doctorate in Biochemistry and Molecular Biology from Howard University and has spent the past 17 years developing and applying translational and clinical research approaches in the areas of molecular oncology and neuroscience. Dr. Carlisle received his post-doctoral training at the NIH where he served at the NCI as a leading member of the Cancer Genome Anatomy Project, and at the National Institute for Neurological Disorders and Stroke.

 

Dr. Carlisle went on to Fox Chase Cancer Center where he helped develop novel technology for monitoring colon cancer progression and identified molecular mechanisms associated with lengthening of telomeres in ovarian cancer cells. Later, Dr. Carlisle joined the Children’s Hospital of Philadelphia; studying the role of chemokines in cancer progression. Dr. Carlisle then moved to Inova Fairfax Hospital, serving as the Department of Neuroscience’s first Principle Investigator for the Inova-George Mason University Neuroscience Translational Research Laboratory. At Inova, he served as director of the Laboratory of Neuro-Oncology where he directed research programs in Neuroblastoma and Traumatic Brain Injury and continues to serve as an Affiliate Professor of Molecular Neuroscience in George Mason University’s Krasnow Institute.

 

Dr. Carlisle went on to Northrop Grumman to serve as a Senior Scientific Advisor for their Health IT unit and Chief Scientist for Precision Healthcare, where he led their efforts to deliver scientific and analytic solutions focused on integrating big data across the patient healthcare ecosystem, driving clinical discovery, and translating this information into clinically actionable information that can be leveraged to improve patient outcomes and reduce healthcare costs. 

 

Dr. Carlisle was recently appointed as Chairman and CEO of the National Alliance against Disparities in Patient Health (NADPH), a Nonprofit Academic Research Network focused on reducing health disparities through science driven community research, technology, education, and career training in the health sciences, where he leads the organization in its efforts to improve health outcomes and create a more sustainable economic model for delivering precision healthcare.

 

In addition to his Volunteer work at the EP3 Foundation, Dr. Carlisle is also an active Volunteer Board Member for the Leukemia & Lymphoma Society (LLS), the EP3 Foundation, and routinely lends his thought leadership and efforts to a number of other social and humanitarian causes.